Venturi Wealth Administration LLC raised its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 73.8% within the third quarter, in response to its most up-to-date disclosure with the SEC. The fund owned 219 shares of the biotechnology firm’s inventory after buying an extra 93 shares throughout the quarter. Venturi Wealth Administration LLC’s holdings in Biogen had been value $42,000 on the finish of the newest quarter.
Various different institutional buyers have additionally just lately made modifications to their positions within the inventory. Vanguard Group Inc. elevated its stake in shares of Biogen by 15.0% within the first quarter. Vanguard Group Inc. now owns 16,570,398 shares of the biotechnology firm’s inventory value $3,573,075,000 after shopping for an extra 2,163,068 shares throughout the interval. Primecap Administration Co. CA elevated its place in shares of Biogen by 0.7% within the second quarter. Primecap Administration Co. CA now owns 16,338,294 shares of the biotechnology firm’s inventory valued at $3,787,543,000 after buying an extra 117,578 shares throughout the interval. Worth T Rowe Associates Inc. MD elevated its place in shares of Biogen by 5.4% within the first quarter. Worth T Rowe Associates Inc. MD now owns 1,589,629 shares of the biotechnology firm’s inventory valued at $342,772,000 after buying an extra 81,283 shares throughout the interval. RA Capital Administration L.P. boosted its holdings in shares of Biogen by 39.0% throughout the first quarter. RA Capital Administration L.P. now owns 740,727 shares of the biotechnology firm’s inventory value $159,723,000 after buying an extra 207,835 shares throughout the interval. Lastly, abrdn plc grew its stake in shares of Biogen by 6.2% within the third quarter. abrdn plc now owns 568,510 shares of the biotechnology firm’s inventory value $110,123,000 after buying an extra 33,333 shares over the past quarter. Hedge funds and different institutional buyers personal 87.93% of the corporate’s inventory.
Analyst Upgrades and Downgrades
A number of analysis companies have weighed in on BIIB. Wolfe Analysis initiated protection on Biogen in a report on Friday. They issued a “peer carry out” score for the corporate. Needham & Firm LLC reaffirmed a “purchase” score and issued a $270.00 value goal on shares of Biogen in a analysis word on Wednesday, October thirtieth. Royal Financial institution of Canada lowered their value goal on shares of Biogen from $292.00 to $269.00 and set an “outperform” score on the inventory in a analysis report on Friday, October 4th. Barclays dropped their goal value on shares of Biogen from $190.00 to $180.00 and set an “equal weight” score for the corporate in a analysis report on Thursday, October thirty first. Lastly, Cantor Fitzgerald reiterated an “obese” score and set a $292.00 value goal on shares of Biogen in a analysis report on Monday, September ninth. Twelve analysts have rated the inventory with a maintain score, sixteen have issued a purchase score and one has assigned a powerful purchase score to the inventory. In accordance with MarketBeat.com, Biogen presently has a consensus score of “Average Purchase” and a consensus goal value of $258.96.
Learn Our Newest Inventory Report on Biogen
Biogen Inventory Efficiency
Shares of BIIB opened at $159.99 on Friday. The corporate has a market cap of $23.31 billion, a price-to-earnings ratio of 14.45, a P/E/G ratio of 1.57 and a beta of -0.06. The enterprise’s fifty day easy shifting common is $186.80 and its two-hundred day easy shifting common is $207.77. Biogen Inc. has a 12 month low of $159.60 and a 12 month excessive of $268.30. The corporate has a present ratio of 1.26, a fast ratio of 0.80 and a debt-to-equity ratio of 0.28.
Biogen (NASDAQ:BIIB – Get Free Report) final launched its quarterly earnings knowledge on Wednesday, October thirtieth. The biotechnology firm reported $4.08 EPS for the quarter, beating the consensus estimate of $3.77 by $0.31. Biogen had a return on fairness of 14.98% and a web margin of 16.81%. The corporate had income of $2.47 billion for the quarter, in comparison with analysts’ expectations of $2.43 billion. Throughout the identical interval final 12 months, the agency posted $4.36 earnings per share. Biogen’s income was down 2.5% in comparison with the identical quarter final 12 months. Analysis analysts anticipate that Biogen Inc. will put up 16.4 earnings per share for the present fiscal 12 months.
Insider Transactions at Biogen
In associated information, insider Priya Singhal bought 431 shares of the agency’s inventory in a transaction that occurred on Tuesday, September third. The shares had been bought at a median value of $204.22, for a complete worth of $88,018.82. Following the sale, the insider now owns 5,316 shares within the firm, valued at roughly $1,085,633.52. This commerce represents a 7.50 % lower of their possession of the inventory. The sale was disclosed in a doc filed with the SEC, which will be accessed by means of the SEC web site. Firm insiders personal 0.16% of the corporate’s inventory.
About Biogen
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative ailments in the US, Europe, Germany, Asia, and internationally. The corporate supplies TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for a number of sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to deal with Alzheimer’s illness; FUMADERM to deal with plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.
See Additionally
Need to see what different hedge funds are holding BIIB? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).
Obtain Information & Scores for Biogen Each day – Enter your electronic mail deal with under to obtain a concise every day abstract of the newest information and analysts’ rankings for Biogen and associated corporations with MarketBeat.com’s FREE every day electronic mail publication.
